FCGR2B and melanoma: These results, especially the trends of the FCGR2B and IL6 pathways, indicate that the immune system in melanoma is actively inducing an immune-suppressive environment, which is contributing to resistance; however, BCC seems to only induce a suppressive environment in responders, indicating that there is a different mechanism of resistance, relying on the simple lack of sufficient activation of immune cells during therapy.